Overview of Canada’s Biomanufacturing and Life Sciences Strategy
Ensuring access to critical vaccines, therapeutics and other life saving medicines is a priority for the Government of Canada. At the outset of the COVID-19 pandemic, the Government of Canada took swift and decisive action to strengthen Canada's biomanufacturing capacity to protect Canadians.
While Canada continues to respond to the current pandemic, we are also implementing a biomanufacturing and life sciences strategy for the future. This strategy has been directly shaped by external advice, from the Vaccine Task Force (VTF), the Therapeutics Task Force, and the Joint Biomanufacturing Subcommittee. In addition, earlier this year, ISED, Health Canada, PHAC and members of the VTF held stakeholder consultations on rebuilding the domestic biomanufacturing sector based on the document Considering the creation of new biomanufacturing capacity for Canada.
Read the full Biomanufacturing and Life Sciences Strategy.
The Strategy consists of 5 pillars to strengthen Canada's biomanufacturing and life sciences sector and is driven by 2 objectives:
- Growing a strong, competitive domestic life sciences sector, with cutting edge biomanufacturing capabilities
- Ensuring preparedness for pandemics or other health emergencies.
Together, the Strategy's 5 pillars will achieve meaningful results for Canadians.
Strong coordinated governance
Integrated and aligned priority setting and investments in research, innovation, and scale-up will ensure Canada's biomanufacturing and life science sector is at the cutting edge, and ready to respond to future health priorities. This will mean more made in Canada vaccines, therapeutics and other life saving medicines.
Federal departments and agencies responsible for supporting the discovery, development, production, and deployment of life saving biomanufacturing and life science capabilities will establish a dedicated and enduring decision-making and implementation function.
Lay the foundation
Strengthening research systems and talent pipeline
Post secondary institutions and affiliated research hospitals are an anchor in innovation for biomanufacturing and life sciences. In order for research to reach its full potential, Canadian scientists need high-performance tools and innovative research spaces and labs to bring their ideas to life.
Canada is committed to making purpose-driven investments in order to drive innovation, equip Canada with expertise, and advance pandemic readiness.
Grow the business
Doubling down on existing and emerging areas of strength
Building out Canada's domestic capabilities in biomanufacturing and life sciences will help improve readiness to respond to future health emergencies. Investing in existing and emerging areas, and Canadian areas of strength, will contribute to Canada's economic growth and increase Canada's contributions to developing the next generation of medicines, while providing greater self-reliance.
Build up, build out
Building public capacity
Building and operationalizing the Biologics Manufacturing Centre on the NRC's Royalmount Avenue site in Montréal is a key component for increasing Canada's domestic biomanufacturing capacity. This new end-to-end biomanufacturing facility will be used to manufacture vaccines and other biologics.
Once operational and Good Manufacturing Practices (GMP)-certified, the Biologics Manufacturing Centre will:
- support the manufacturing of vaccine candidates and/or biologics in response to the current and future pandemics
- ensure Canada is prepared to safely manufacture large quantities of vaccines using good manufacturing practices
- ensure the Government of Canada can access and supply future vaccines in Canada for Canadians
- support growth of Canada's biomanufacturing production capacity, knowledge transfer and collaboration.
The Government of Canada is also supporting other construction projects to improve Canada's biomanufacturing capabilities. Take an in-depth look at all the facilities across Canada.
Enabling innovation by ensuring best-in-class regulation
Canada will continue to leverage its best-in-class regulatory system to support increased innovation, and world-class expertise and infrastructure for clinical trials. Support in health innovation from discovery to application will make Canada a more attractive destination for biomanufacturing and life sciences ecosystem firms.
- Date modified: